YOUR BUSINESS AUTHORITY
Springfield, MO
Gilead Sciences agreed to buy Kite Pharma for $11 billion, people familiar with the matter told Dow Jones Newswires.
The all-cash deal would give Gilead access to Kite Pharma's new technology designed to harness the body's immune system to fight cancer.
Foster City, California-based Gilead's portfolio includes infectious-disease treatments.
Read more from Dow Jones Newswires.
Nixa Superintendent Gearl Loden weighs in on A-F grade cards.
SBJ announces executive newsroom hires
Thanksgiving staple recalled at Costco
HBA of Greater Springfield executive officer to retire
Timeshare exit company owner sentenced for tax evasion
Warren Buffett donates $5.5B worth of Berkshire Hathaway shares
Letter to the Editor: No half-baked cake for our kids. No half-baked school grades, either.